PankoMab-GEX™: Phase 1 Dose Escalation Study

计划入组 74 人 · 首次发布于 2010 年 10 月 18 日

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

计划入组 69 人 · 首次发布于 2019 年 7 月 16 日

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

计划入组 40 人 · 首次发布于 2017 年 6 月 7 日

TA-MUC1 x IL15(Glycotope)

Anti-TA-MUC1 bispecific antibody(Glycotope)

Anti TA-MUC1 antibody drug conjugate (Daiichi Sankyo Company)

TA BIOSCIENCES PTE. LTD.

Singapore

LI TA SHEN MEDICAL TRADER

Singapore

新怡平康（北京）食品有限公司

Daiichi Sankyo Acquires Solid Tumour ADC Gatipotuzumab from Glycotope for $132.5 Million

Daiichi Sankyo's DS-3939 Shows Promising Early Results in Advanced Solid Tumors Phase 1/2 Trial

NK Cell Engager Development Faces Mounting Setbacks as BeOne Medicines and Novartis Discontinue Programs